메뉴 건너뛰기




Volumn 117, Issue 21, 2011, Pages 5013-5020

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

Author keywords

clinical outcome; ErbB2; HER2 ECD; metastatic breast cancer; response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

EID: 80054817785     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26101     Document Type: Article
Times cited : (22)

References (25)
  • 1
    • 0022588467 scopus 로고
    • Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
    • Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986; 319: 230-234. (Pubitemid 16128786)
    • (1986) Nature , vol.319 , Issue.6050 , pp. 230-234
    • Yamamoto, T.1    Ikawa, S.2    Akiyama, T.3
  • 2
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182. (Pubitemid 17231334)
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 3
    • 0034327895 scopus 로고    scopus 로고
    • Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
    • Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000; 18: 3651-3664.
    • (2000) J Clin Oncol. , vol.18 , pp. 3651-3664
    • Pauletti, G.1    Dandekar, S.2    Rong, H.3
  • 6
    • 0141615794 scopus 로고    scopus 로고
    • Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer
    • DOI 10.1373/49.10.1579
    • Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP,. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem. 2003; 49: 1579-1598. (Pubitemid 37194212)
    • (2003) Clinical Chemistry , vol.49 , Issue.10 , pp. 1579-1598
    • Carney, W.P.1    Neumann, R.2    Lipton, A.3    Leitzel, K.4    Ali, S.5    Price, C.P.6
  • 13
    • 34547097500 scopus 로고    scopus 로고
    • Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy
    • DOI 10.1002/cncr.22825
    • Sandri MT, Johansson HA, Zorzino L, et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 2007; 110: 509-517. (Pubitemid 47106138)
    • (2007) Cancer , vol.110 , Issue.3 , pp. 509-517
    • Sandri, M.T.1    Johansson, H.A.2    Zorzino, L.3    Salvatici, M.4    Passerini, R.5    Maisonneuve, P.6    Rocca, A.7    Peruzzotti, G.8    Colleoni, M.9
  • 14
    • 53149107465 scopus 로고    scopus 로고
    • Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    • Ali SM, Carney WP, Esteva FJ, et al. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008; 113: 1294-1301.
    • (2008) Cancer. , vol.113 , pp. 1294-1301
    • Ali, S.M.1    Carney, W.P.2    Esteva, F.J.3
  • 15
    • 51149117030 scopus 로고    scopus 로고
    • Drug insight: Intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer
    • Cameron DA, Stein S,. Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol. 2008; 9: 512-520.
    • (2008) Nat Clin Pract Oncol. , vol.9 , pp. 512-520
    • Cameron, D.A.1    Stein, S.2
  • 17
    • 46449113024 scopus 로고    scopus 로고
    • Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
    • Gomez HL, Doval DC, Chavez MA, et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol. 2008; 26: 2999-3005.
    • (2008) J Clin Oncol. , vol.26 , pp. 2999-3005
    • Gomez, H.L.1    Doval, D.C.2    Chavez, M.A.3
  • 19
    • 0037268795 scopus 로고    scopus 로고
    • The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer
    • DOI 10.1309/TY6M-DWB0-G2BU-6D5F
    • Carney WP,. The emerging role of monitoring serum HER-2/neu oncoprotein levels in women with metastatic breast cancer. Lab Medicine. 2003; 34: 58-64. (Pubitemid 36197260)
    • (2003) Laboratory Medicine , vol.34 , Issue.1 , pp. 58-64
    • Carney, W.P.1
  • 20
    • 33644528230 scopus 로고    scopus 로고
    • Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
    • Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res. 2005; 7: R436-R443.
    • (2005) Breast Cancer Res. , vol.7
    • Esteva, F.J.1    Cheli, C.D.2    Fritsche, H.3
  • 21
    • 14644401104 scopus 로고    scopus 로고
    • Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    • DOI 10.1093/annonc/mdi059
    • Fornier MN, Seidman AD, Schwartz MK, et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol. 2005; 16: 234-239. (Pubitemid 40309302)
    • (2005) Annals of Oncology , vol.16 , Issue.2 , pp. 234-239
    • Fornier, M.N.1    Seidman, A.D.2    Schwartz, M.K.3    Ghani, F.4    Thiel, R.5    Norton, L.6    Hudis, C.7
  • 22
    • 63749132329 scopus 로고    scopus 로고
    • Utility of serum HER2 extracellular domain assessment in clinical decision making: Pooled analysis of four trials of trastuzumab in metastatic breast cancer
    • Lennon S, Barton C, Banken L, et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. J Clin Oncol. 2009; 27: 1685-1693.
    • (2009) J Clin Oncol. , vol.27 , pp. 1685-1693
    • Lennon, S.1    Barton, C.2    Banken, L.3
  • 23
    • 73949125361 scopus 로고    scopus 로고
    • Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
    • Finn RS, Gagnon R, Di LA, Press MF, Arbushites M, Koehler M,. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009; 27: 5552-5558.
    • (2009) J Clin Oncol. , vol.27 , pp. 5552-5558
    • Finn, R.S.1    Gagnon, R.2    Di, L.A.3    Press, M.F.4    Arbushites, M.5    Koehler, M.6
  • 24
    • 52049111595 scopus 로고    scopus 로고
    • Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor
    • Witters L, Scherle P, Friedman S, et al. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 2008; 68: 7083-7089.
    • (2008) Cancer Res. , vol.68 , pp. 7083-7089
    • Witters, L.1    Scherle, P.2    Friedman, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.